UNLABELLED: Background and aims Nearly half of all patients with inflammatory bowel disease (IBD) use the Internet as a source of information for their disease. We analyzed the source, content and accuracy of IBD videos found on YouTube - one of the most popular websites in the United States - and assessed the demographic variables of the viewers. METHODS: The 100 most viewed videos with relevant information on IBD were analyzed. We included only English language videos that were less than 20 min in length and primarily focused on IBD. Those with no sound/poor sound quality were excluded. More than 30 variables were analyzed. RESULTS: Adults of 45-54 years old (95.1%) comprised the most common age group of viewers. Forty-eight percent of videos focused on Crohn's disease (CD), 32.0% on ulcerative colitis (UC), and 20.0% on both. Overall content for patient education was poor. Videos discussing alternative treatment options were more likely to depict patients' personal experience (73.9% vs. 2.4%) (p<0.001) and be an advertisement compared to patient education videos (78.3% vs. 0) (p<0.001). Videos discussing patient education had a higher number of favorites (mean 25.0 vs. 5.5) (p<0.001), comments (mean 22.0 vs. 5.0) (p<0.022) and "likes" (mean 19.0 vs. 9.0) (p=0.025) than the ones discussing alternative treatment options. CONCLUSIONS: YouTube videos on IBD are popular but a poor source of patient education. Healthcare providers and professional societies should provide more educational materials using this powerful Internet tool to counteract the misleading information, especially for the targeted age group (45-54 years).
UNLABELLED: Background and aims Nearly half of all patients with inflammatory bowel disease (IBD) use the Internet as a source of information for their disease. We analyzed the source, content and accuracy of IBD videos found on YouTube - one of the most popular websites in the United States - and assessed the demographic variables of the viewers. METHODS: The 100 most viewed videos with relevant information on IBD were analyzed. We included only English language videos that were less than 20 min in length and primarily focused on IBD. Those with no sound/poor sound quality were excluded. More than 30 variables were analyzed. RESULTS: Adults of 45-54 years old (95.1%) comprised the most common age group of viewers. Forty-eight percent of videos focused on Crohn's disease (CD), 32.0% on ulcerative colitis (UC), and 20.0% on both. Overall content for patient education was poor. Videos discussing alternative treatment options were more likely to depict patients' personal experience (73.9% vs. 2.4%) (p<0.001) and be an advertisement compared to patient education videos (78.3% vs. 0) (p<0.001). Videos discussing patient education had a higher number of favorites (mean 25.0 vs. 5.5) (p<0.001), comments (mean 22.0 vs. 5.0) (p<0.022) and "likes" (mean 19.0 vs. 9.0) (p=0.025) than the ones discussing alternative treatment options. CONCLUSIONS: YouTube videos on IBD are popular but a poor source of patient education. Healthcare providers and professional societies should provide more educational materials using this powerful Internet tool to counteract the misleading information, especially for the targeted age group (45-54 years).
Authors: Eldin Dzubur; Carine Khalil; Christopher V Almario; Benjamin Noah; Deeba Minhas; Mariko Ishimori; Corey Arnold; Yujin Park; Jonathan Kay; Michael H Weisman; Brennan M R Spiegel Journal: Arthritis Care Res (Hoboken) Date: 2019-02 Impact factor: 4.794
Authors: Shivani U Thanawala; Claire A Beveridge; Amanda B Muir; Mary Jo Strobel; Amity Westcott-Chavez; Marina Serper; Yu-Xiao Yang; Kristle L Lynch Journal: Dis Esophagus Date: 2021-11-11 Impact factor: 2.822
Authors: Alexis C Prince; Arifa Moosa; Miranda C E Lomer; Dianne P Reidlinger; Kevin Whelan Journal: Health Expect Date: 2014-06-17 Impact factor: 3.377
Authors: Craig Hansen; Julia D Interrante; Elizabeth C Ailes; Meghan T Frey; Cheryl S Broussard; Valerie J Godoshian; Courtney Lewis; Kara N D Polen; Amanda P Garcia; Suzanne M Gilboa Journal: Pharmacoepidemiol Drug Saf Date: 2015-11-05 Impact factor: 2.890